Theranostics in immuno-oncology using nanobody derivatives

Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short‐lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this...

Descripción completa

Detalles Bibliográficos
Autores principales: Lecocq, Quentin, De Vlaeminck, Yannick, Hanssens, Heleen, D'Huyvetter, Matthias, Raes, Geert, Goyvaerts, Cleo, Keyaerts, Marleen, Devoogdt, Nick, Breckpot, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831473/
https://www.ncbi.nlm.nih.gov/pubmed/31695800
http://dx.doi.org/10.7150/thno.34941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831473/
https://www.ncbi.nlm.nih.gov/pubmed/31695800
http://dx.doi.org/10.7150/thno.34941

Ejemplares similares